Pricing Log in Create free account

Monte Rosa Therapeutics, Inc. (GLUE) vs Savara Inc. (SVRA)

Monte Rosa Therapeutics, Inc. and Savara Inc. are both Biotechnology companies. Monte Rosa Therapeutics, Inc. and Savara Inc. are of similar size ($899.9M and $874.5M). Savara Inc. has the higher net margin (0.00% vs −186.2%) and the lower return on invested capital (−12,213.2% vs 0.00%). Across the 14 metrics below, Monte Rosa Therapeutics, Inc. leads on 8 and Savara Inc. on 6.

Valuation

Metric GLUE SVRA Biotechnology median
P/E n/m n/m 10.60
P/S 15.18 n/m 9.40
P/B 2.15 8.53 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 6.97 n/m 9.02
Earnings yield (13.35%) (12.01%) (32.88%)
Free cash flow yield (16.33%) (9.04%) (23.13%)

Profitability

Metric GLUE SVRA Biotechnology median
Gross margin 100.00% 0.00% 68.51%
Operating margin (214.46%) 0.00% 0.00%
Net margin (186.24%) 0.00% 0.00%
Free cash flow margin (247.98%) 0.00% 0.00%
Return on equity (35.30%) (105.48%) (51.96%)
Return on assets (22.63%) (78.28%) (46.06%)
Return on invested capital 0.00% (12,213.18%) 0.00%

Growth

Metric GLUE SVRA Biotechnology median
Revenue growth (TTM) (61.26%) — 6.76%
EPS growth (last fiscal year) 53.06% (10.42%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GLUE SVRA Biotechnology median
Debt to equity 0.00 0.21 0.00
Current ratio 10.32 10.13 4.97
Net debt to EBITDA 8.22 1.64 1.01

Dividend

Metric GLUE SVRA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric GLUE SVRA Biotechnology median
Market cap 874.46m 899.91m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack